NP said a few days ago that they were talking to a lot of people. Leronlimab is a good opportunity for BP because of its low risk, 32 indications of which 22 cancers, if one fails the other will work, and because of its ease of use and without SAE it can be easily combined, which is important in oncology, the same is said for NASH. So far I have not been in a stock that has a BO, but here I think the chances are great, though I would like to start with a mono pivotal trial and a basket trial for 10 cancers. NP previously mentioned 6 cancers, now it says 10 cancers for the basket trial.